Table 3. CD209 -336A/G and Clinical Correlates of Tuberculosis.
| Clinical Correlates | Status | CD209 -336A/G variant* | Total | P value | Odds Ratio | 95% CI | |
| AA+AG | GG | ||||||
| Sex | Male | 573 (73.4%) | 208 (26.6%) | 781 | 0.293 | 0.871 | 0.673–1.127 |
| Female | 389 (76.0%) | 123 (24.0%) | 512 | ||||
| HIV | Negative | 831 (73.8%) | 295 (26.2%) | 1126 | 0.255 | 1.306 | 0.823–2.073 |
| Positive | 92 (78.6%) | 25 (21.4%) | 117 | ||||
| Age Groups | 0–19 | 100 (75.8%) | 32 (24.2%) | 132 | 0.996 | ||
| 20–29 | 363 (74.1%) | 127 (25.9%) | 490 | ||||
| 30–39 | 264 (74.6%) | 90 (25.4%) | 354 | ||||
| 40–49 | 145 (74.4%) | 50 (25.6%) | 195 | ||||
| 50–99 | 90 (73.8%) | 32 (26.2%) | 122 | ||||
| Haemoptysis | No | 281 (77.2%) | 83 (22.8%) | 364 | 0.858 | 0.959 | 0.604–1.523 |
| Yes | 113 (77.9%) | 32 (22.2%) | 145 | ||||
| Cavitation | No | 194 (69.8%) | 84 (30.2%) | 278 | 0.0000313 | 0.421 | 0.278–0.636 |
| Yes | 236 (84.6%) | 43 (15.4%) | 279 | ||||
| No. Zones affected | 1–3 | 182 (77.1%) | 54 (22.9%) | 236 | 0.931 | 0.982 | 0.658–1.468 |
| 4–6 | 247 (77.4%) | 72 (22.6%) | 319 | ||||
| Duration of cough | 0–8 weeks | 271 (79.0%) | 72 (21.0%) | 343 | 0.259 | 1.285 | 0.831–1.989 |
| >8 weeks | 123 (74.5%) | 42 (25.5%) | 165 | ||||
| Degree of sputum positivity | + | 12 (66.7%) | 6 (33.3%) | 18 | 0.604 | ||
| ++ | 162 (75.7%) | 52 (24.3%) | 214 | ||||
| +++ | 337 (76.8%) | 102 (23.2%) | 439 | ||||
*
Combined West African tuberculosis case control data. Significance level of P<0.05 is indicated in bold.